Screener
Edgewise Therapeutics, Inc. EWTX Business Segments — Segment Reporting Other Item Amount
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The source filing: Edgewise Therapeutics, Inc.’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 8:05 AM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020112
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Contracted research expense | $87,987 | $80,214 | $57,497 |
| Personnel expense | 47,606 | 35,797 | 24,604 |
| Stock-based compensation expense | 34,752 | 24,712 | 17,556 |
| Other segment expense(a) | 18,977 | 16,040 | 13,149 |
| Depreciation | 2,084 | 2,069 | 1,551 |
| Segment net loss | (191,406) | (158,832) | (114,357) |
| Reconciliation of net loss | |||
| Interest income | 23,611 | 25,019 | 14,194 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Edgewise Therapeutics, Inc.'s business segments — segment reporting other item amount?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — segment reporting other item amount of $4.74M in Q4 2025.
- How has Edgewise Therapeutics, Inc.'s business segments — segment reporting other item amount changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — segment reporting other item amount increased by 18.3% year-over-year, from $4.01M to $4.74M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — segment reporting other item amount?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — segment reporting other item amount has grown at a 20.1% compound annual growth rate (CAGR), from $13.15M to $18.98M.
- What does business segments — segment reporting other item amount mean?
- Represents residual expenses or income items that are not classified under primary operational categories. This metric is used to capture unique or non-recurring financial impacts that are specific to the segment's reporting structure. It helps investors reconcile total segment performance by accounting for miscellaneous financial adjustments.
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — segment reporting other item amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude